Mbarara University of Science and Technology - Succeed We Must




NAME:  Muzoora, Conrad K.

POSITION TITLE:  Lecturer Internal Medicine



Mbarara University Science & Tech., Uganda     - MBChB 2002 Medicine
Mbarara University Science & Tech., Uganda     -  M.Med 2007 Internal Medicine
University of California at San Francisco TICR   -2009-10 HIV Clinical Research

A. Personal Statement
Dr. Muzoora is a HIV physician-scientist with formal training in clinical research.  He has conducted three clinical trials involving cryptococcal meningitis.  As a senior lecturer he is influential in setting policy, developing treatment guidelines, and teaching undergraduate and postgraduate medical trainees.  His research interest is in HIV Aids and associated opportunistic infections specifically Cryptococcus meningitis and Tuberculosis.

B. Positions and Honors.
2002 - 2003 Intern Doctor in Internal Medicine & Obstetrics/Gyn., Mbarara Univ. Teaching Hospital Uganda
2003 - 2004 Medical Officer and Acting Medical Director; Mbarara Nursing Home, Uganda
2004 - 2007 Assistant Lecturer & Senior House Officer (Resident), Internal Medicine, Mbarara Univ., Uganda
2007-present Physician and Lecturer, Internal Medicine, Mbarara University
2008-present Coordinator for postgraduate studies, Department of Medicine, Mbarara University
2008-present Member of the Faculty Research Ethics review Board, Mbarara University
2009 - 2010 HIV Clinical Scholars Fellowship, University of California at San Francisco (UCSF)
2010, 2012 Acting Head of Department of Internal Medicine, Mbarara University

2003-present Uganda Medical Association, Member
2004-present Mbarara University Academic Staff Association, Member

2007 Research Fellow in Mbarara Univ. Sci & Tech./HARVARD/MAYBACH Foundation Programme

C. Peer-reviewed publications
1. Optimizing Network Connectivity for Mobile Health Technologies in sub-Saharan
Africa. Siedner MJ, Lankowski A, Musinga D, Jackson J, Muzoora C, Hunt PW, Martin JN,
Bangsberg DR, Haberer JE. PLoS One. 2012;7(9):e45643. doi: 10.1371/journal.pone.0045643. Epub 2012 Sep 28.
2.  Rethinking the "pre" in pre-therapy counseling: no benefit of additional visits prior to
therapy on adherence or viremia in Ugandans initiating ARVs. Siedner MJ, Lankowski A, Haberer JE, Kembabazi A, Emenyonu N, Tsai AC, Muzoora C, Geng E, Martin JN, Bangsberg DR. PLoS One. 2012;7(6):e39894. Epub 2012 Jun 26.
 3.  Food insecurity, depression and the modifying role of social support among people living
with HIV/AIDS in rural Uganda. Tsai AC, Bangsberg DR, Frongillo EA, Hunt PW, Muzoora C, Martin JN, Weiser SD. Soc Sci Med. 2012 Jun;74(12):2012-9. Epub 2012 Mar 23.
4.  No Association Found Between Traditional Healer Use and Delayed Antiretroviral Initiation in Rural    Uganda. Horwitz RH, Tsai AC, Maling S, Bajunirwe F, Haberer JE, Emenyonu N, Muzoora C, Hunt PW, Martin JN, Bangsberg DR. AIDS Behav. 2012 Jan 13.

5. Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal
meningitis. Muzoora CK, Kabanda T, Ortu G, Ssentamu J, Hearn P, Mwesigye J, Longley N, Jarvis
JN, Jaffar S, Harrison TS. J Infect. 2012 Jan;64(1):76-81. Epub 2011 Nov 4.

6. The role of SNPs in the α-chain of the IL-7R gene in CD4+ T-cell recovery in HIVinfected
African patients receiving suppressive cART. Rajasuriar R, Booth DR, Gouillou M, Spelman T, James I, Solomon A, Chua K, Stewart G, Deeks S, Bangsberg DR, Muzoora C, Cameron PU, Hunt P, Martin J, Lewin SR. Genes Immun. 2012 Jan;13(1):83-93. doi: 10.1038/gene.2011.65. Epub 2011 Sep 22.
7. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected
Ugandans initiating antiretroviral therapy. Hunt PW, Cao HL, Muzoora C, Ssewanyana I, Bennett J,  Emenyonu N, Kembabazi A, Neilands TB, Bangsberg DR, Deeks SG, Martin JN. AIDS. 2011 Nov 13;25(17):2123-31. doi: 10.1097/QAD.0b013e32834c4ac1.
8. Should antiretroviral therapy be delayed for 10 weeks for patients treated with fluconazole for cryptococcal meningitis? Bicanic T, Jarvis JN, Muzoora C, Harrison TS. Clin Infect Dis. 2010 Oct 15;51(8):986-7; author reply 987-9.
9. Independent association between rate of clearance of infection and clinical outcome of
HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients.
Bicanic T, Muzoora C, Brouwer AE, Meintjes G, Longley N, Taseera K, Rebe K, Loyse
A, Jarvis J, Bekker LG, Wood R, Limmathurotsakul D, Chierakul W, Stepniewska K,
White NJ, Jaffar S, Harrison TS. Clin Infect Dis. 2009 Sep 1;49(5):702-9.
10. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal
meningitis in southwestern Uganda. Longley N, Muzoora C, Taseera K, Mwesigye J, Rwebembera J, Chakera A, Wall E, Andia I, Jaffar S, Harrison TS. Clin Infect Dis. 2008 Dec 15;47(12):1556-61.
11. Handheld Point-of-Care Cerebrospinal Fluid Lactate Testing Predicts Bacterial
Meningitis in Uganda. Albert Majwala, Rebecca Burke, William Patterson, Relana Pinkerton, Conrad
Muzoora, L. Anthony Wilson, and Christopher C. Moore*. Am. J. Trop. Med. Hyg.,88(1), 2013, pp. 127–131 doi:10.4269/ajtmh.2012.12-0447
12. Member of Guidelines development group World Health Organisation. Rapid Advice
Diagnosis, Prevention and Management of Cryptococc al Disease in HIV –infected
Adults, Adolescents and Children.

D. Research Support.
1. NIH NIAID U01 AI089244-02  Boulware (PI)     7/15/2010-6/30/2015
Trial for the Optimal Timing of HIV Therapy after Cryptococcal Meningitis
  Implementation of a multisite, international randomized clinical trial in Africa to determine when is the optimal time to initiate HIV therapy after cryptococcal meningitis to maximize survival.
Role:  Co-Investigator, Site PI.

2. NIH NIAID 1K23AI084544-01  Geng, Elvin H (PI)    9/25/2009- 7/31/2013
National Institute of Allergy and Infectious Diseases
Title: “Causes of Early Mortality in HIV-infected Patients Starting Antiretroviral Therapy in Africa”
Role Co-Investigator






MUST Forum | Staff Directory | Computing Services | Library | Contact Us
© Mbarara University of Science and Technology – All Rights Reserved Copyrights 2020